Arthur J. Gallagher Expands Service Offering With Buyout
Zacks Investment Research | Dec 17, 2018 10:25PM ET
Arthur J. Gallagher & Co. (NYSE:AJG) has acquired Preston-Patterson Co., Inc. The acquisition will help the company enhance its portfolio of offering. The terms of the deal have been kept under wraps.
Founded in 1947, Conshohocken, PA-based Preston-Patterson Co. is a retail property and casualty insurance broker. The company caters to broadcasters and media clients across the United States. This apart, the company caters to the demand of commercial clients and personal lines of clients, with focus on coastal property exposures along the Atlantic Seaboard. Addition of Preston-Patterson Co. will thus add capabilities to Arthur J. Gallagher’s array of insurance brokerage services for broadcasters and media clients.
Arthur J. Gallagher evolved from a small retail presence in Australia, Canada and New Zealand to one of the top five brokers. The company acquired 459 entities through 2002 and 2017. In the first nine months of 2018, the company closed 27 buyouts, with annualized revenues of about $234 million. This Zacks Rank #2 (Buy) insurance broker has also been expanding outside the United States as evident from its last few buyouts. Its inorganic pipeline remains strong with about $500 million of revenues. A solid capital position has been aiding the company to pursue mergers.
You can see industry ’s increase of 7.4%. The company’s expansion policy to ramp up its growth and a strong capital position should continue to drive shares higher.
Other Integrations in the Insurance Space
Recently, Brown & Brown, Inc.’s (NYSE:BRO) subsidiary, Brown & Brown of Kentucky, Inc., acquired Dealer Associates, Inc. to ramp up its dealer services team in Southwest. Arch Capital Group Ltd (NASDAQ:ACGL) acquired McNeil & Co. to boost its underwriting business. In the last month, Marsh & McLennan Companies, Inc.'s (NYSE:MMC) unit Mercer acquired investment consulting, alternatives consulting, and wealth management operations of Pavilion Financial Corporation to provide wider and deeper global research, and specialist resources to its consultants and clients.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
Get The News You Want
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.